Discovery of Novel and Potent Dual PARP1/ERK Inhibitors as a Promising Strategy for Cancer Therapy.

ulixertinib (BVD-523) - BioMed Valley Discoveries

Lynparza (olaparib) - Merck (MSD), AstraZeneca

http://www.ncbi.nlm.nih.gov/pubmed/41739621

Dongqing Guo; Haiping Hao; Hong Wang; Jing Liu; Kaiyuan Cong; Lei Huang; Qihua Zhu; Shiqi Wu; Wenhui Zhang; Wenxin Yan; Yi Zou; Ying Bai; Yuchen Bian; Yuepeng Chen; Yungen Xu; Yupei Su; Zhaohui Guan

Feb 25, 2026